Current Status of Cost Utility Analyses in Total Joint Arthroplasty: A Systematic Review

Clinical Orthopaedics and Related Research

Volumn 473, Issue 5, 2015, Pages 1815-1827

  Nwachukwu, Benedict U ^a   Bozic, Kevin J ^b   Schairer, William W ^a   Bernstein, Jaime L ^c   Jevsevar, David S ^d   Marx, Robert G ^a   Padgett, Douglas E ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; COST BENEFIT ANALYSIS; COST CONTROL; DEVICES; ECONOMICS; HEALTH CARE COST; HIP ARTHROPLASTY; HIP PROSTHESIS; HUMAN; KNEE ARTHROPLASTY; KNEE PROSTHESIS; ODDS RATIO; TREATMENT OUTCOME;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HIP PROSTHESIS; HUMANS; KNEE PROSTHESIS; ODDS RATIO; TREATMENT OUTCOME;

EID: 84939884377     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-014-3964-4     Document Type: Review

References (64)

1. Amiri AR, Kanesalingam K, Cro S, Casey AT. Does source of funding and conflict of interest influence the outcome and quality of spinal research? Spine J. 2014;14:308–314.
2. Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin. 2008;24:753–768.
3. Botteman MF, Caprini J, Stephens JM, Nadipelli V, Bell CF, Pashos CL, Cohen AT. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther. 2002;24:1960–1986; discussion 1938.
4. Bozic KJ, Chiu V, Slover JD, Immerman I, Kahn JG. Patient preferences and willingness to pay for arthroplasty surgery in patients with osteoarthritis of the hip. J Arthroplasty. 2012;27:503–506.e502.
5. Bozic KJ, Morshed S, Silverstein MD, Rubash HE, Kahn JG. Use of cost-effectiveness analysis to evaluate new technologies in orthopaedics. The case of alternative bearing surfaces in total hip arthroplasty. J Bone Joint Surg Am. 2006;88:706–714.
6. Bozic KJ, Pui CM, Ludeman MJ, Vail TP, Silverstein MD. Do the potential benefits of metal-on-metal hip resurfacing justify the increased cost and risk of complications? Clin Orthop Relat Res. 2010;468:2301–2312.
7. Bozic KJ, Saleh KJ, Rosenberg AG, Rubash HE. Economic evaluation in total hip arthroplasty: analysis and review of the literature. J Arthroplasty. 2004;19:180–189.
8. Brauer CA, Neumann PJ, Rosen AB. Trends in cost effectiveness analyses in orthopaedic surgery. Clin Orthop Relat Res. 2007;457:42–48.
9. Brauer CA, Rosen AB, Olchanski NV, Neumann PJ. Cost-utility analyses in orthopaedic surgery. J Bone Joint Surg Am. 2005;87:1253–1259.
10. Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32–44.
11. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27:71–76.
12. Courville XF, Tomek IM, Kirkland KB, Birhle M, Kantor SR, Finlayson SR. Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2012;33:152–159.
13. Cummins JS, Tomek IM, Kantor SR, Furnes O, Engesaeter LB, Finlayson SR. Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty. J Bone Joint Surg Am. 2009;91:634–641.
14. Cutler D, Wikler E, Basch P. Reducing administrative costs and improving the health care system. N Engl J Med. 2012;367:1875–1878.
15. Daigle ME, Weinstein AM, Katz JN, Losina E. The cost-effectiveness of total joint arthroplasty: a systematic review of published literature. Best Pract Res Clin Rheumatol. 2012;26:649–658.
16. Day JS, Lau E, Ong KL, Williams GR, Ramsey ML, Kurtz SM. Prevalence and projections of total shoulder and elbow arthroplasty in the United States to 2015. J Shoulder Elbow Surg. 2010;19:1115–1120.
17. de Verteuil R, Imamura M, Zhu S, Glazener C, Fraser C, Munro N, Hutchison J, Grant A, Coyle D, Coyle K, Vale L. A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip. Health Technol Assess. 2008;12:iii–iv, ix–223.
18. Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am. 2004;86:963–974.
19. Fisher ES, Bell JE, Tomek IM, Esty AR, Goodman DC. Trends and Regional Variation in Hip, Knee, and Shoulder Replacement. 2010. Available at: http://www.dartmouthatlas.org/downloads/reports/Joint_Replacement_0410.pdf. Accessed September 9, 2014.
20. Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis. 2001;32:419–430.
21. Gold MR, Sofaer S, Siegelberg T. Medicare and cost-effectiveness analysis: time to ask the taxpayers. Health Aff (Millwood). 2007;26:1399–1406.
22. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332–342.
23. Hussman JM, Lanctot KL, Paes B. The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. J Med Econ. 2013;16:115–124.
24. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780–785.
25. Kuye IO, Jain NB, Warner L, Herndon JH, Warner JJ. Economic evaluations in shoulder pathologies: a systematic review of the literature. J Shoulder Elbow Surg. 2012;21:367–375.
26. Lansky D, Nwachukwu BU, Bozic KJ. Using financial incentives to improve value in orthopaedics. Clin Orthop Relat Res. 2012;470:1027–1037.
27. Lavernia CJ, Alcerro JC. Quality of life and cost-effectiveness 1 year after total hip arthroplasty. J Arthroplasty. 2011;26:705–709.
28. Lawless BM, Greene M, Slover J, Kwon YM, Malchau H. Does age or bilateral disease influence the value of hip arthroplasty? Clin Orthop Relat Res. 2012;470:1073–1078.
29. Lin J, Wilbur WJ. PubMed related articles: a probabilistic topic-based model for content similarity. BMC Bioinformatics. 2007;8:423.
30. Lin MM, Goldsmith JD, Resch SC, DeAngelis JP, Ramappa AJ. Histologic examinations of arthroplasty specimens are not cost-effective: a retrospective cohort study. Clin Orthop Relat Res. 2012;470:1452–1460.
31. Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, Wright EA, Holt HL, Solomon DH, Yelin E, Paltiel AD, Katz JN. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med. 2009;169:1113–1121; discussion 1121–1122.
32. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–1012.
33. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the USD 50,000-per-QALY threshold. N Engl J Med. 2014;371:796–797.
34. Neumann PJ, Palmer JA, Daniels N, Quigley K, Gold MR, Chao S. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care. 2008;14:185–188.
35. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516–1522.
36. Noordin S, Wright JG, Howard A. Relationship between declared funding support and level of evidence. J Bone Joint Surg Am. 2010;92:1647–1651.
37. Novak EJ, Silverstein MD, Bozic KJ. The cost-effectiveness of computer-assisted navigation in total knee arthroplasty. J Bone Joint Surg Am. 2007;89:2389–2397.
38. Nwachukwu BU, Hamid KS, Bozic KJ. Measuring value in orthopaedic surgery. JBJS Reviews. 2013;1\1\e.2. Available at http://reviews.jbjs.org/content/1/1/e2.full-text.pdf+html. Accessed September 9, 2014.
39. Oberlander J. Unfinished journey—a century of health care reform in the United States. N Engl J Med. 2012;367:585–590.
40. Odum SM, Troyer JL, Kelly MP, Dedini RD, Bozic KJ. A cost-utility analysis comparing the cost-effectiveness of simultaneous and staged bilateral total knee arthroplasty. J Bone Joint Surg Am. 2013;95:1441–1449.
41. Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW, Hay JW. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9:53–61.
42. Okike K, Kocher MS, Mehlman CT, Heckman JD, Bhandari M. Nonscientific factors associated with acceptance for publication in The Journal of Bone and Joint Surgery (American Volume). J Bone Joint Surg Am. 2008;90:2432–2437.
43. Okike K, Kocher MS, Mehlman CT, Heckman JD, Bhandari M. Publication bias in orthopaedic research: an analysis of scientific factors associated with publication in the Journal of Bone and Joint Surgery (American Volume). J Bone Joint Surg Am. 2008;90:595–601.
44. Okike K, Kocher MS, Torpey JL, Nwachukwu BU, Mehlman CT, Bhandari M. Level of evidence and conflict of interest disclosure associated with higher citation rates in orthopedics. J Clin Epidemiol. 2011;64:331–338.
45. Orszag PR, Emanuel EJ. Health care reform and cost control. N Engl J Med. 2010;363:601–603.
46. Peterson LE, Goodman C, Karnes EK, Chen CJ, Schwartz JA. Assessment of the quality of cost analysis literature in physical therapy. Phys Ther. 2009;89:733–755.
47. Ruiz D Jr, Koenig L, Dall TM, Gallo P, Narzikul A, Parvizi J, Tongue J. The direct and indirect costs to society of treatment for end-stage knee osteoarthritis. J Bone Joint Surg Am. 2013;95:1473–1480.
48. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172–1177.
49. Schousboe JT, Brown GA. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. J Bone Joint Surg Am. 2013;95:1256–1264.
50. Schwartz JA, Pearson SD. Cost consideration in the clinical guidance documents of physician specialty societies in the United States. JAMA Intern Med. 2013;173:1091–1097.
51. Sharifi E, Sharifi H, Morshed S, Bozic K, Diab M. Cost-effectiveness analysis of periacetabular osteotomy. J Bone Joint Surg Am. 2008;90:1447–1456.
52. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339–1341.
53. Slobogean GP, Verma A, Giustini D, Slobogean BL, Mulpuri K. MEDLINE, EMBASE, and Cochrane index most primary studies but not abstracts included in orthopedic meta-analyses. J Clin Epidemiol. 2009;62:1261–1267.
54. Slover J, Espehaug B, Havelin LI, Engesaeter LB, Furnes O, Tomek I, Tosteson A. Cost-effectiveness of unicompartmental and total knee arthroplasty in elderly low-demand patients. A Markov decision analysis. J Bone Joint Surg Am. 2006;88:2348–2355.
55. Slover J, Hoffman MV, Malchau H, Tosteson AN, Koval KJ. A cost-effectiveness analysis of the arthroplasty options for displaced femoral neck fractures in the active, healthy, elderly population. J Arthroplasty. 2009;24:854–860.
56. Slover JD, Rubash HE, Malchau H, Bosco JA. Cost-effectiveness analysis of custom total knee cutting blocks. J Arthroplasty. 2012;27:180–185.
57. Slover JD, Tosteson AN, Bozic KJ, Rubash HE, Malchau H. Impact of hospital volume on the economic value of computer navigation for total knee replacement. J Bone Joint Surg Am. 2008;90:1492–1500.
58. Smart KA, Lanctot KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ. 2010;13:453–463.
59. Soohoo NF, Sharifi H, Kominski G, Lieberman JR. Cost-effectiveness analysis of unicompartmental knee arthroplasty as an alternative to total knee arthroplasty for unicompartmental osteoarthritis. J Bone Joint Surg Am. 2006;88:1975–1982.
60. Spiegel BM, Targownik LE, Kanwal F, Derosa V, Dulai GS, Gralnek IM, Chiou CF. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology. 2004;127:403–411.
61. Suter LG, Paltiel AD, Rome BN, Solomon DH, Thornhill TS, Abrams SK, Katz JN, Losina E. Placing a price on medical device innovation: the example of total knee arthroplasty. PloS One. 2013;8:e62709.
62. Toal MJ. Industry sponsored bias: NICE may be biased too. BMJ (Clin Res Ed). 2011;342:d474.
63. Watters TS, Browne JA, Orlando LA, Wellman SS, Urbaniak JR, Bolognesi MP. Cost-effectiveness analysis of free vascularized fibular grafting for osteonecrosis of the femoral head. J Surg Orthop Adv. 2011;20:158–167.
64. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253–1258.